VEGF Immunoexpression in Prostate Adenocarcinoma.
Andrei Pănuş1, Cristiana Eugenia Simionescu2, Petru Octavian Drăgoescu3
1PhD Student, Department of Pathology, University of Medicine and Pharmacy of Craiova, Romania.
Current Health Sciences Journal
|July 2, 2021
Summary
Vascular endothelial growth factor (VEGF) fuels tumor growth. Higher VEGF-A levels in prostate adenocarcinomas correlate with aggressive features, indicating its role in prostate cancer progression and identifying aggressive lesions.
Area of Science:
- Oncology
- Molecular Biology
- Pathology
Background:
- Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and progression.
- Vascular Endothelial Growth Factor (VEGF) is a key regulator of angiogenesis.
- Prostate adenocarcinoma (PA) is a common malignancy where angiogenesis plays a significant role.
Purpose of the Study:
- To investigate the expression of VEGF-A in prostate adenocarcinomas.
- To correlate VEGF-A immunoexpression with established prognostic parameters of prostate cancer.
- To assess the potential of VEGF-A as a biomarker for aggressive prostate lesions.
Main Methods:
- Analysis of VEGF-A immunoexpression in 61 prostate adenocarcinoma samples.
- Correlation of VEGF scores with serum PSA levels, tumor growth patterns, tumor grade, and clinical stage.
Main Results:
- Elevated VEGF scores were observed in PAs with serum PSA values > 20 ng/ml.
- Higher VEGF expression was associated with complex or mixed tumor growth patterns.
- Increased VEGF levels correlated with high-grade and advanced-stage prostate adenocarcinomas.
Conclusions:
- VEGF-A is involved in the angiogenesis of prostate cancer.
- VEGF-A immunoexpression serves as a useful marker for identifying aggressive prostate adenocarcinomas.
- Targeting VEGF may be a potential therapeutic strategy for aggressive prostate cancer.
